These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35001477)

  • 1. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
    Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
    Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Glycemic Outcomes During the MiniMed
    Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
    Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
    Forlenza GP; Pinhas-Hamiel O; Liljenquist DR; Shulman DI; Bailey TS; Bode BW; Wood MA; Buckingham BA; Kaiserman KB; Shin J; Huang S; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2019 Jan; 21(1):11-19. PubMed ID: 30585770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
    Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
    Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus.
    Pei Y; Ke W; Lu J; Lin Y; Zhang Z; Peng Y; Bi Y; Li Y; Hou J; Zhang X; Chen X; Treminio Y; Lee SW; Shin J; Rhinehart AS; Vigersky RA; Mu Y
    Diabetes Technol Ther; 2023 Oct; 25(10):718-725. PubMed ID: 37578804
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and Safety of Real-Life Usage of MiniMed 670G Automode in Children with Type 1 Diabetes Less than 7 Years Old.
    Salehi P; Roberts AJ; Kim GJ
    Diabetes Technol Ther; 2019 Aug; 21(8):448-451. PubMed ID: 31166801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
    Arunachalum S; Velado K; Vigersky RA; Cordero TL
    J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast-Acting Insulin Aspart Use with the MiniMed
    Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
    Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.
    Garg SK; Grunberger G; Weinstock R; Lawson ML; Hirsch IB; DiMeglio LA; Pop-Busui R; Philis-Tsimikas A; Kipnes M; Liljenquist DR; Brazg RL; Kudva YC; Buckingham BA; McGill JB; Carlson AL; Criego AB; Christiansen MP; Kaiserman KB; Griffin KJ; Forlenza GP; Bode BW; Slover RH; Keiter A; Ling C; Marinos B; Cordero TL; Shin J; Lee SW; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Jan; 25(1):1-12. PubMed ID: 36472543
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
    Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
    Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
    [No Abstract]   [Full Text] [Related]  

  • 12. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.
    Nimri R; Grosman B; Roy A; Nir J; Fisch Shvalb N; Kurtz N; Loewenthal N; Gillon-Keren M; Muller I; Atlas E; Phillip M
    Diabetes Technol Ther; 2021 Apr; 23(4):268-276. PubMed ID: 33185480
    [No Abstract]   [Full Text] [Related]  

  • 13. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
    Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
    Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
    Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
    Garg SK; Weinzimer SA; Tamborlane WV; Buckingham BA; Bode BW; Bailey TS; Brazg RL; Ilany J; Slover RH; Anderson SM; Bergenstal RM; Grosman B; Roy A; Cordero TL; Shin J; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2017 Mar; 19(3):155-163. PubMed ID: 28134564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-Month Effectiveness of Advanced
    Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
    Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
    Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
    Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world performance of the MiniMed™ 670G system in Europe.
    Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
    Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
    [No Abstract]   [Full Text] [Related]  

  • 20. Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems.
    Forlenza GP; Dai Z; Niu F; Shin JJ
    Diabetes Technol Ther; 2024 Mar; 26(S3):7-16. PubMed ID: 38377321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.